普洛药业: 2025年半年度报告

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Apeloa Pharmaceutical Co., Ltd. for the first half of 2025, indicating a decline in revenue and net profit while emphasizing ongoing efforts in innovation and operational efficiency [1][6][8]. Financial Performance - The company reported a revenue of CNY 5,444.49 million, a decrease of 15.31% compared to the previous year [6][8]. - The net profit attributable to shareholders was CNY 520.55 million, down 13.59% year-on-year [6][8]. - Basic earnings per share decreased by 9.14% to CNY 0.4861 [6][8]. Business Overview - The company operates in four main business segments: raw material intermediates, CDMO (Contract Development and Manufacturing Organization), pharmaceuticals, and medical beauty raw materials [7][21]. - The raw material intermediates business includes various series such as cephalosporins and penicillins, while the CDMO segment has seen a 20.32% increase in revenue [9][10]. Industry Context - The biopharmaceutical industry is undergoing significant transformation, driven by technological advancements and an aging population, with the global pharmaceutical market projected to reach USD 2.5 trillion by 2030 [12][13]. - The CDMO market is expected to grow from USD 146.29 billion in 2024 to USD 180 billion in 2025, indicating a robust demand for integrated pharmaceutical services [12][13]. Strategic Initiatives - The company is committed to its "2030 Development Strategy," focusing on enhancing its core competencies in raw materials, strengthening CDMO capabilities, and expanding its pharmaceutical offerings [7][8]. - Ongoing investments in R&D and technology platforms aim to improve production efficiency and product quality, with a focus on automation and digitalization [19][24]. Research and Development - The company employs 1,155 R&D personnel, with significant investments in various technology platforms to support its API and CDMO businesses [23][24]. - Recent achievements include the approval of three API products and one domestic formulation, reflecting the company's commitment to innovation [14][15]. Regulatory Environment - The pharmaceutical industry is experiencing a wave of policy changes aimed at enhancing drug quality and pricing mechanisms, which are expected to support sustainable growth [13][26]. - The company has successfully passed multiple audits from international regulatory bodies, ensuring compliance with high-quality standards [25][26].